Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Concord Biotech
Join Channel
Consolidated Standalone

Concord Biotech

₹1518 16 | 1.1%

Market Cap ₹15881 Cr.

Stock P/E 54.7

P/B 11.1

Current Price ₹1518

Book Value ₹ 136.6

Face Value 1

52W High ₹1712

Dividend Yield 0.45%

52W Low ₹ 900

Edit Ratio

Concord Biotech Research see more...

Overview Inc. Year: 1984Industry: Pharmaceuticals & Drugs

Concord Biotech Ltd is a renowned biotechnology company with a global presence, specializing in the research, development, and production of high-quality biopharmaceuticals and specialty chemicals. Founded on a commitment to innovation and sustainability, Concord Biotech has established itself as a leader in the biotech industry. The company's core expertise lies in microbial fermentation and bioprocess technology, enabling them to create a diverse portfolio of products that range from antibiotics and enzymes to nutraceuticals. With state-of-the-art facilities and a talented team of scientists and engineers, Concord Biotech consistently delivers cutting-edge solutions for healthcare, agriculture, and industrial sectors. Dedicated to environmental responsibility, Concord Biotech places a strong emphasis on sustainable practices, ensuring their operations align with global eco-friendly standards. Their unwavering dedication to quality, research, and ethical business practices has earned them a stellar reputation in the biotech community, making them a trusted partner for clients worldwide.

Read More..

Concord Biotech Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Concord Biotech Quarterly Results

#(Fig in Cr.) Jun 2022 Sep 2022 Dec 2022 Jun 2023 Sep 2023 Dec 2023
Net Sales 181 159 241 195 262 241
Other Income 8 6 9 7 8 8
Total Income 189 165 250 201 270 249
Total Expenditure 116 121 129 123 143 135
Operating Profit 72 44 121 79 127 114
Interest 1 1 1 1 1 0
Depreciation 14 13 14 13 13 14
Exceptional Income / Expenses 0 0 0 0 0 0
Profit Before Tax 58 30 106 65 113 100
Provision for Tax 15 8 27 17 29 26
Profit After Tax 43 22 79 48 84 75
Adjustments 6 -0 -2 6 -3 3
Profit After Adjustments 49 22 77 54 81 78
Adjusted Earnings Per Share 0.4 2.1 7.4 5.2 7.7 7.4

Concord Biotech Profit & Loss

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 512 617 713 853 939
Other Income 31 14 23 35 32
Total Income 544 631 736 888 970
Total Expenditure 308 289 439 505 530
Operating Profit 236 342 297 384 441
Interest 1 1 6 10 3
Depreciation 21 28 50 54 54
Exceptional Income / Expenses 0 0 0 0 0
Profit Before Tax 213 313 238 322 384
Provision for Tax 45 78 63 82 99
Profit After Tax 169 235 175 240 286
Adjustments 0 -0 0 0 4
Profit After Adjustments 169 235 175 240 290
Adjusted Earnings Per Share 16.2 22.4 16.7 22.9 27.7

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 20% 19% 0% 0%
Operating Profit CAGR 29% 18% 0% 0%
PAT CAGR 37% 12% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR NA% NA% NA% NA%
ROE Average 20% 21% 21% 21%
ROCE Average 27% 27% 27% 27%

Concord Biotech Balance Sheet

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 770 999 1103 1290
Minority's Interest 0 0 0 0
Borrowings 36 56 31 6
Other Non-Current Liabilities 20 21 23 26
Total Current Liabilities 223 236 344 376
Total Liabilities 1049 1313 1502 1699
Fixed Assets 240 546 573 593
Other Non-Current Assets 271 159 296 378
Total Current Assets 539 607 633 728
Total Assets 1049 1313 1502 1699

Concord Biotech Cash Flow

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 4 2 5 1
Cash Flow from Operating Activities 155 167 207 246
Cash Flow from Investing Activities -113 -195 -112 -158
Cash Flow from Financing Activities -43 31 -100 -85
Net Cash Inflow / Outflow -1 3 -4 3
Closing Cash & Cash Equivalent 2 5 1 3

Concord Biotech Ratios

# Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 16.15 22.45 16.72 22.95
CEPS(Rs) 18.18 25.08 21.5 28.11
DPS(Rs) 0.6 7.42 5.12 6.83
Book NAV/Share(Rs) 73.62 95.52 105.45 123.3
Core EBITDA Margin(%) 39.14 52.14 37.73 39.1
EBIT Margin(%) 41.07 49.89 33.56 37.22
Pre Tax Margin(%) 40.85 49.72 32.72 36.12
PAT Margin (%) 32.33 37.35 24.1 26.93
Cash Profit Margin (%) 36.4 41.73 30.99 32.99
ROA(%) 16.11 19.89 12.43 15
ROE(%) 21.94 26.55 16.64 20.06
ROCE(%) 26.23 32.96 21.66 26.7
Receivable days 128.17 104.76 102.99 103.56
Inventory Days 77.69 76.85 87.67 83.4
Payable days 200.1 192.42 144.1 179.16
PER(x) 0 0 0 0
Price/Book(x) 0 0 0 0
Dividend Yield(%) 0 0 0 0
EV/Net Sales(x) 0.11 0.06 -0.03 -0
EV/Core EBITDA(x) 0.23 0.1 -0.06 -0
Net Sales Growth(%) 0 20.42 15.56 19.67
EBIT Growth(%) 0 46.17 -22.35 36.18
PAT Growth(%) 0 39.02 -25.53 37.25
EPS Growth(%) 0 38.99 -25.51 37.25
Debt/Equity(x) 0.06 0.09 0.05 0.02
Current Ratio(x) 2.41 2.57 1.84 1.93
Quick Ratio(x) 1.91 1.92 1.27 1.37
Interest Cover(x) 183.92 299.68 39.72 33.85
Total Debt/Mcap(x) 0 0 0 0

Concord Biotech Shareholding Pattern

# Sep 2023 Dec 2023 Mar 2024
Promoter 44.08 44.08 44.08
FII 7.3 7 6.48
DII 8.12 8.4 8.41
Public 40.5 40.52 41.03
Others 0 0 0
Total 100 100 100

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 21%
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 44.08%.
  • Debtor days have increased from 144.1 to 179.16days.
  • Stock is trading at 11.1 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Concord Biotech News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!